Seeing

the invisible
Today’s presentation

• Charles Laycock, CEO

• Objectives

• Markets & marketing

• Ophthalmology

• Defence & other markets

• Outlook
Seeing
the invisible

Conventional Image
2006 objectives
Completed

• Completed milestones 1 - 4 of DSTO CTD contract 9

• Constructed prototype camera test bed for CTD 9
contract
• Obtained first order from GE Healthcare 9
• Completed ophthalmology proof of concept for 9
auto-refractor
• Simplified capital structure and converted options 9
2007 objectives
Completed

• Letter of agreement with international ophthalmology 9

manufacturer

• Finalise test work on auto-refractor prototype and

handover to manufacturer – February 2007

• License agreement with ophthalmology equipment

manufacturer – March 2007

• CTD defence contract milestones 5 – 8, including the first

military field demonstration in March 2007
Commercialisation

• Geography - 75% west coast USA

• Reference site e.g. GE Healthcare

• Connections & networks

• Technical people to technical people

• Resources - develop or market

Target markets

High value markets in both biological and material areas:

• Medical
Ophthalmology, pathology and academic research

• Bio-pharmaceutical
Automated cell analysis, assay and targeting

• Nanotechnology
Electron microscopy, X-ray imaging, semi-conductor quality
assurance

• Defence
CTD contract
Market focus

• Platform technology with many applications

• One area of focus - niche high return

• Looking for best risk reward ratio

• Ophthalmology

• Existing technical knowledge

• Known growth market

Ophthalmology
• Growth market - especially with aging populations

• Wave front sensing is the “must have” technology

• QPI will provide ophthalmologists with better measurement

& software tool for early detection of eye diseases and
general eye health

• Current target 4 to 5 products

Ophthalmology

THEM US

Shack Hartman
Auto-refractor

• Measures quality (power) of

eye’s vision for eyeware.

• QPI gives megapixel resolution

• Measure more subtle

aberrations in eyes

• Better diagnosis & better

prescriptions

• Infra-red LED light so no OHS

issues
Progress
Defence and homeland security

• Changing military requirements brings need for new

technologies to:
• negate camouflage
• allow for passive, undetectable surveillance and target
ranging
• DSTO CTD contract - three years & up to $2.7 mill.
• Developing QPI to enable imaging over greater distances
• International interest from other key military organisations
• Large markets but long development lead times
The concept
Seeing
the invisible

Conventional Image Iatia Processed

Shape Image
Progress to date
• Completed and received
payment milestones 1 to 4
Picture of
• Prototype camera test bed prototype
constructed

• First military field trial

scheduled for March 2007
Outlook

• Further direct marketing will generate additional

opportunities

• 2007 & 2008 New product development & license

agreements in all 4 markets

• 2007 November launch of auto-refractor

• 2008 Projected first year profit, strong growth thereafter

Why Iatia will be a success

• Proven patented technology

• Successful products in the market

• Extensive application pipeline

• Applications that target large as well as niche markets

• Agreements & alliances with high quality organisations

• Research and development spending

• Experienced management
“We find this product quite remarkable”
Dr. David J Brenner, Professor of Radiation Oncology & Public
Health, Columbia University Medical Centre, New York, USA

Live unstained human fibroblast cells

Seeing
the invisible